Vemurafenib improves overall survival compared to dacarbazine in advanced BRAFV600E mutated melanoma: an update from the phase III randomized, open-label, multicenter BRIM3 trial

P Lorigan; A Hauschild; GA McArthur; C Robert; JB Haanen; P Ascierto; J Larkin; R Dummer; C Garbe; A Testori; Maio Michele; D Hogg; C Lebbe; T Jouary; D Schadendorf; A Ribas; SJ O'Day; JA Sosman; J Kirkwood; A Eggermont; B Dreno; K Nolop; J Li; B Nelson; A Joe; RJ Lee; KT Flaherty; PB Chapman

Vemurafenib improves overall survival compared to dacarbazine in advanced BRAFV600E mutated melanoma: an update from the phase III randomized, open-label, multicenter BRIM3 trial

P Lorigan, A Hauschild, GA McArthur, C Robert, JB Haanen, P Ascierto, J Larkin, R Dummer, C Garbe, A Testori, Maio Michele, D Hogg, C Lebbe, T Jouary, D Schadendorf, A Ribas, SJ O'Day, JA Sosman, J Kirkwood, A EggermontB Dreno, K Nolop, J Li, B Nelson, A Joe, RJ Lee, KT Flaherty, PB Chapman

Research output: Contribution to conference › Poster

Original language	English
Publication status	Published - 2011
Event	International Melanoma Congress 'Pathology Symposium & Primary Care Update' - Tampa, Florida Duration: 10 Nov 2011 → 14 Nov 2011

Conference

Conference	International Melanoma Congress 'Pathology Symposium & Primary Care Update'
City	Tampa, Florida
Period	10/11/11 → 14/11/11

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

Lorigan, P., Hauschild, A., McArthur, GA., Robert, C., Haanen, JB., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Michele, M., Hogg, D., Lebbe, C., Jouary, T., Schadendorf, D., Ribas, A., O'Day, SJ., Sosman, JA., Kirkwood, J., ... Chapman, PB. (2011). Vemurafenib improves overall survival compared to dacarbazine in advanced BRAFV600E mutated melanoma: an update from the phase III randomized, open-label, multicenter BRIM3 trial. Poster session presented at International Melanoma Congress 'Pathology Symposium & Primary Care Update', Tampa, Florida.

@conference{9f70b3169bd24d2fa793f660fceb94a5,

title = "Vemurafenib improves overall survival compared to dacarbazine in advanced BRAFV600E mutated melanoma: an update from the phase III randomized, open-label, multicenter BRIM3 trial",

author = "P Lorigan and A Hauschild and GA McArthur and C Robert and JB Haanen and P Ascierto and J Larkin and R Dummer and C Garbe and A Testori and Maio Michele and D Hogg and C Lebbe and T Jouary and D Schadendorf and A Ribas and SJ O'Day and JA Sosman and J Kirkwood and A Eggermont and B Dreno and K Nolop and J Li and B Nelson and A Joe and RJ Lee and KT Flaherty and PB Chapman",

year = "2011",

language = "English",

note = "International Melanoma Congress 'Pathology Symposium & Primary Care Update' ; Conference date: 10-11-2011 Through 14-11-2011",

}

Lorigan, P, Hauschild, A, McArthur, GA, Robert, C, Haanen, JB, Ascierto, P, Larkin, J, Dummer, R, Garbe, C, Testori, A, Michele, M, Hogg, D, Lebbe, C, Jouary, T, Schadendorf, D, Ribas, A, O'Day, SJ, Sosman, JA, Kirkwood, J, Eggermont, A, Dreno, B, Nolop, K, Li, J, Nelson, B, Joe, A, Lee, RJ, Flaherty, KT & Chapman, PB 2011, 'Vemurafenib improves overall survival compared to dacarbazine in advanced BRAFV600E mutated melanoma: an update from the phase III randomized, open-label, multicenter BRIM3 trial', International Melanoma Congress 'Pathology Symposium & Primary Care Update', Tampa, Florida, 10/11/11 - 14/11/11.

Vemurafenib improves overall survival compared to dacarbazine in advanced BRAFV600E mutated melanoma: an update from the phase III randomized, open-label, multicenter BRIM3 trial. / Lorigan, P; Hauschild, A; McArthur, GA et al.
2011. Poster session presented at International Melanoma Congress 'Pathology Symposium & Primary Care Update', Tampa, Florida.

Research output: Contribution to conference › Poster

TY - CONF

T1 - Vemurafenib improves overall survival compared to dacarbazine in advanced BRAFV600E mutated melanoma: an update from the phase III randomized, open-label, multicenter BRIM3 trial

AU - Lorigan, P

AU - Hauschild, A

AU - McArthur, GA

AU - Robert, C

AU - Haanen, JB

AU - Ascierto, P

AU - Larkin, J

AU - Dummer, R

AU - Garbe, C

AU - Testori, A

AU - Michele, Maio

AU - Hogg, D

AU - Lebbe, C

AU - Jouary, T

AU - Schadendorf, D

AU - Ribas, A

AU - O'Day, SJ

AU - Sosman, JA

AU - Kirkwood, J

AU - Eggermont, A

AU - Dreno, B

AU - Nolop, K

AU - Li, J

AU - Nelson, B

AU - Joe, A

AU - Lee, RJ

AU - Flaherty, KT

AU - Chapman, PB

PY - 2011

Y1 - 2011

M3 - Poster

T2 - International Melanoma Congress 'Pathology Symposium & Primary Care Update'

Y2 - 10 November 2011 through 14 November 2011

ER -

Lorigan P, Hauschild A, McArthur GA, Robert C, Haanen JB, Ascierto P et al.. Vemurafenib improves overall survival compared to dacarbazine in advanced BRAFV600E mutated melanoma: an update from the phase III randomized, open-label, multicenter BRIM3 trial. 2011. Poster session presented at International Melanoma Congress 'Pathology Symposium & Primary Care Update', Tampa, Florida.